Literature DB >> 32681257

Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl4-induced Liver Fibrosis Rats.

Hou-Gang Li1, Peng-Tao You2, Yu Xia1, Yu Cai3, Yi-Jun Tu1, Meng-Heng Wang1, Wan-Ci Song3, Tai-Min Quan3, Hui-Ying Ren3, Yan-Wen Liu1, Han-Xiong Dan1, Shi-Qing Xu4.   

Abstract

Yu Gan Long (YGL) is a Chinese traditional herbal formula which has been reported to attenuate liver fibrosis for many years and we have explored its anti-fibrotic mechanism through blocking transforming growth factor (TGF-β) in the previous study. But the mechanisms associated with platelet-derived growth factor (PDGF)-BB remain obscure. In this study, we further investigated the mechanism of YGL reducing carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Our results showed that YGL suppressed CCl4-induced upregulation of collagen IV (Col IV), type HI precollagen (PCHI), hyaluronuc acid (HA) and laminin (LN), which are implicated in liver fibrosis. Also, YGL reduced the α-smooth muscle actin (α-SMA) expression, which acts as the indicator of liver fibrosis. Furthermore, YGL decreased the serum levels of hepatic stellate cell (HSC) mitogen PDGF-BB and inflammation cytokines, including TNF-α, IL-1β, IL-6. Markers involved in liver fibrosis, such as Ras, p-Raf-1, p-ERK1/2, p-JNK, p-P38, p-PI3K, p-AKT, p-JAKl, p-STAT3 were downregulated significantly after treatment with YGL. Our results indicated that YGL ameliorated CCl4-induced liver fibrosis by reducing inflammation cytokines production, and suppressing Ras/ERK, PI3K/AKT, and JAK1/STAT3 signaling pathways, which provided further evidence towards elucidation of the anti-fibrotic mechanism of YGL.

Entities:  

Keywords:  JAK1/STAT3; PI3K/AKT; Ras/ERK; Yu Gan Long; liver fibrosis; traditional Chinese herbal therapy

Mesh:

Substances:

Year:  2020        PMID: 32681257     DOI: 10.1007/s11596-020-2211-3

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  1 in total

1.  Antifibrotic effects of tanshinol in experimental hepatic fibrosis by targeting PI3K/AKT/mTOR/p70S6K1 signaling pathways.

Authors:  Ruqin Peng; Shaozhan Wang; Rong Wang; Yuanyuan Wang; Yan Wu; Yongfang Yuan
Journal:  Discov Med       Date:  2017-02       Impact factor: 2.970

  1 in total
  1 in total

1.  Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.

Authors:  Justin F Creeden; Zachary A Kipp; Mei Xu; Robert M Flight; Hunter N B Moseley; Genesee J Martinez; Wang-Hsin Lee; Khaled Alganem; Ali S Imami; Megan R McMullen; Sanjoy Roychowdhury; Atta M Nawabi; Jennifer A Hipp; Samir Softic; Steven A Weinman; Robert McCullumsmith; Laura E Nagy; Terry D Hinds
Journal:  Hepatology       Date:  2022-04-08       Impact factor: 17.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.